Palace 'no reaction' to Mon Tulfo’s vaccination of smuggled Sinopharm jab | Inquirer News
Close  

Palace ‘no reaction’ to Mon Tulfo’s vaccination of smuggled Sinopharm jab

By: - Reporter / @KAguilarINQ
/ 04:14 PM February 24, 2021
Palace 'no reaction' to Mon Tulfo’s vaccination of smuggled Sinopharm jab

In this April 10, 2020, photo released by Xinhua News Agency, a staff member holds up a sample of a potential COVID-19 vaccine at a production plant of SinoPharm in Beijing.(Zhang Yuwei/Xinhua via AP)

MANILA, Philippines — Malacañang on Wednesday distanced itself from columnist Mon Tulfo’s vaccination using smuggled Covid-19 vaccines made by China’s Sinopharm, saying it will just let the Food and Drug Administration (FDA) and the Ombudsman investigate.

ADVERTISEMENT

“Wala pong ganiyang polisiya dahil kung may ganiyan pong polisiya, siguro commercial quantity na ang kumalat noong mga bakuna na hindi naaprubahan. Pero inaantay po talaga natin ang aksiyon ng FDA sa mga bagay-bagay na ito,” presidential spokesperson Harry Roque said in an online briefing Wednesday when sought to comment on the issue.

(There’s no policy as such. If there’s any, maybe there’s already a commercial quantity of the vaccine that has yet to be approved. We’re waiting for FDA’s action on this matter.)

FEATURED STORIES

Tulfo, the country’s special envoy to China, admitted in his newspaper column that he was vaccinated against Covid-19 in October 2020 along with other officials.

He even said he was willing to give up his special envoy post to become a local distributor of Sinopharm’s vaccine.

The FDA has since said it will probe Tulfo’s vaccination.

“Wala po akong reaksyon dyan dahil sa panahon ng pandemya, naiintindihan ko po na talagang maraming gusto magkaroon ng proteksyon pero ang sinasabi natin sa lahat, antayin po natin na dumaan sa proseso for our own interest,” Roque said.

(I don’t have any reaction to that because, during times of a pandemic, I understand that some want to have protection but what we’re saying is, it should undergo the process for our own interest.)

“We have no opinion whatsoever, we leave that to the Ombudsman,” he continued.

Roque kept mum when pressed to comment on Tulfo’s claim that President Rodrigo Duterte had already spoken with the supposed local representative of Sinopharm to ask for its Covid-19 vaccine.

ADVERTISEMENT

“Now, whether or not he has talked to a representative, hindi ko po alam. If I will admit, I was in this adjacent room when Mon Tulfo was there but I could not really hear what they were discussing ‘no,” Roque said.

“Pero sa akin, I don’t understand the big deal about the Mon Tulfo write-up. That’s an account of Mon Tulfo and if you want verification please contact Mon Tulfo because I cannot answer on his behalf,” he added.

Malacañang previously said President Rodrigo Duterte prefers to receive the vaccine developed by Sinopharm.

However, FDA said Sinopharm has yet to apply for an emergency use authorization or EUA that would allow it to have its Covid-19 vaccine administered to local patients.

KGA

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link .

Read Next
Don't miss out on the latest news and information.

Subscribe to INQUIRER PLUS to get access to The Philippine Daily Inquirer & other 70+ titles, share up to 5 gadgets, listen to the news, download as early as 4am & share articles on social media. Call 896 6000.

TAGS: Coronavirus, COVID-19, FDA, Food and Drug Administration, Health, Malacañang, Mon Tulfo, Ombudsman, Palace, pandemic, SARS-CoV-2, Sinopharm, vaccine, Virus
For feedback, complaints, or inquiries, contact us.


© Copyright 1997-2021 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.